- Home
- ACHR vs RVMD Comparison
ACHR vs RVMD Comparison
Compare ACHR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHR
- RVMD
- Stock Information
- Founded
- ACHR 2018
- RVMD 2014
- Country
- ACHR United States
- RVMD United States
- Employees
- ACHR N/A
- RVMD N/A
- Industry
- ACHR Aerospace
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACHR Industrials
- RVMD Health Care
- Exchange
- ACHR Nasdaq
- RVMD Nasdaq
- Market Cap
- ACHR 6.3B
- RVMD 7.5B
- IPO Year
- ACHR N/A
- RVMD 2020
- Fundamental
- Price
- ACHR $9.26
- RVMD $38.40
- Analyst Decision
- ACHR Strong Buy
- RVMD Strong Buy
- Analyst Count
- ACHR 7
- RVMD 13
- Target Price
- ACHR $13.43
- RVMD $69.85
- AVG Volume (30 Days)
- ACHR 28.5M
- RVMD 1.9M
- Earning Date
- ACHR 08-11-2025
- RVMD 08-06-2025
- Dividend Yield
- ACHR N/A
- RVMD N/A
- EPS Growth
- ACHR N/A
- RVMD N/A
- EPS
- ACHR N/A
- RVMD N/A
- Revenue
- ACHR N/A
- RVMD N/A
- Revenue This Year
- ACHR N/A
- RVMD N/A
- Revenue Next Year
- ACHR $636.40
- RVMD $387.56
- P/E Ratio
- ACHR N/A
- RVMD N/A
- Revenue Growth
- ACHR N/A
- RVMD N/A
- 52 Week Low
- ACHR $2.82
- RVMD $29.17
- 52 Week High
- ACHR $13.92
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- ACHR 41.24
- RVMD 58.95
- Support Level
- ACHR $9.06
- RVMD $35.62
- Resistance Level
- ACHR $9.81
- RVMD $37.91
- Average True Range (ATR)
- ACHR 0.49
- RVMD 1.29
- MACD
- ACHR -0.03
- RVMD 0.32
- Stochastic Oscillator
- ACHR 22.99
- RVMD 100.00
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.